Mechanisms of immunity in acutely decompensated cirrhosis and acute‐on‐chronic liver failure
Liver International · 2025-03 · 45 (3)
DOI: 10.1111/liv.15644 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 27.06.2023. Verfasst von Cornelius Engelmann und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department, Division of Hepatology and Gastroenterology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, Liver Cirrhosis, Inflammation. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Berlin Institute of Health, Else Kröner-Fresenius-Stiftung, European Association for the Study of the Liver.
Abstract (Originalsprache)
The identification of systemic inflammation (SI) as a central player in the orchestration of acute‐on‐chronic liver failure (ACLF) has opened new avenues for the understanding of the pathophysiological mechanisms underlying this disease condition. ACLF, which develops in patients with acute decompensation of cirrhosis, is characterized by single or multiple organ failure and high risk of short‐term (28‐day) mortality. Its poor outcome is closely associated with the severity of the systemic inflammatory response. In this review, we describe the key features of SI in patients with acutely decompensated cirrhosis and ACLF, including the presence of a high blood white cell count and increased levels of inflammatory mediators in systemic circulation. We also discuss the main triggers (i.e. pathogen‐ and damage‐associated molecular patterns), the cell effectors (i.e. neutrophils, monocytes and lymphocytes), the humoral mediators (acute phase proteins, cytokines, chemokines, growth factors and bioactive lipid mediators) and the factors that influence the systemic inflammatory response that drive organ failure and mortality in ACLF. The role of immunological exhaustion and/or immunoparalysis in the context of exacerbated inflammatory responses that predispose ACLF patients to secondary infections and re‐escalation of end‐organ dysfunction and mortality are also reviewed. Finally, several new potential immunogenic therapeutic targets are debated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Department, Division of Hepatology and Gastroenterology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Berlin Institute of Health, Berlin, Germany.
- Institute for Liver and Digestive Health, University College London, London, UK.
- European Foundation for the Study of Chronic Liver Failure (EF CLIF) and Grifols Chair, Barcelona, Spain.
- Biochemistry and Molecular Genetics Service, Hospital Clínic-IDIBAPS CIBERehd, Barcelona, Spain.
- Department of Biomedical Sciences, University of Barcelona, Barcelona, Spain.
ORCID-Profile: Cornelius Engelmann, Ingrid W Zhang, Joan Clària
Förderung
- Berlin Institute of Health
- Else Kröner-Fresenius-Stiftung
- European Association for the Study of the Liver
- European Union's Horizon 2020
- Generalitat de Catalunya
- Spanish Ministerio de Ciencia e Innovación
Zitieren
APA
Engelmann, C., Zhang, I. W., & Clària, J. (2025). Mechanisms of immunity in acutely decompensated cirrhosis and acute‐on‐chronic liver failure. Liver International, 45(3). https://doi.org/10.1111/liv.15644
Vancouver
Engelmann C, Zhang IW, Clària J. Mechanisms of immunity in acutely decompensated cirrhosis and acute‐on‐chronic liver failure. Liver International. 2025;45(3). doi:10.1111/liv.15644
BibTeX
@article{Engelmann2025,
author = {Engelmann, Cornelius and Zhang, Ingrid W and Clària, Joan},
title = {Mechanisms of immunity in acutely decompensated cirrhosis and acute‐on‐chronic liver failure},
journal = {Liver International},
year = {2025},
volume = {45},
number = {3},
doi = {10.1111/liv.15644}
}
EUVIMED